Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC — Stella

Recruiting

Back to LA HNSCC trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing, Chongqing Municipality

Key details

Phase

Safety & dosing

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Enrollment target

~42 participants

Started

March 2025

Primary completion

March 2027

Age range

18 Years and older

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov